What is ImmunityBio, Inc.'s gross profit?

ImmunityBio, Inc. (IBRX) reported gross profit of $43.97M in Q1 2026.

How has ImmunityBio, Inc.'s gross profit changed year-over-year?

ImmunityBio, Inc.'s gross profit increased by 167.1% year-over-year, from $16.46M to $43.97M.

What is the long-term trend for ImmunityBio, Inc.'s gross profit?

Over 3 years (2022 to 2025), ImmunityBio, Inc.'s gross profit has grown at a 676.9% compound annual growth rate (CAGR), from $240K to $112.54M.

ImmunityBio, Inc. IBRX Gross Profit

Gross Profit at other companies

Bristol-Myers SquibbBMY

$8.07B-1.2%

Johnson & JohnsonJNJ

$15.96B+9.8%

Merck & Co.MRK

$12.09B-0.2%

Gilead SciencesGILD

$5.52B+7.6%

IncyteINCY

——

ExelixisEXEL

——

Segments

By segment

See full

Reportable Segment$43.97M+167%

Other financials

Income statement

See full

Revenue$44.2M+168%

Operating income-$69.8M-8.3%

Net income-$632.8M-388%

EPS (diluted)-$0.62-313%

Balance sheet

See full

Cash & equivalents$205.2M+238%

Total debt$445.4M+32.2%

Total equity-$870.0M-47.1%

Total assets$646.6M+113%

Cash flow

See full

Operating cash flow-$75.4M+12.3%

CapEx$1.8M+58.4%

Free cash flow-$77.1M+11.4%

Valuation

See full

Market cap$7.71B+208%

Enterprise value$7.95B+187%

P/S54.7×-25.4×

Profitability

See full

Gross margin99.3%-0.5pp

Operating margin-185.4%-83.3pp

Net margin-606.2%-212pp

FCF margin-212%-95.8pp

Returns & leverage

See full

Return on equity-119.3%—

Debt / equity0.1×—

Current ratio6.7×+4.4×

Where this comes from

Calculated from ImmunityBio, Inc.’s reported figures.

$44.2Mtotal revenue−$238.0Ktotal cost of revenue=$43.97M

The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about ImmunityBio, Inc.'s gross profit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ImmunityBio, Inc.'s gross profit?: ImmunityBio, Inc. (IBRX) reported gross profit of $43.97M in Q1 2026.
How has ImmunityBio, Inc.'s gross profit changed year-over-year?: ImmunityBio, Inc.'s gross profit increased by 167.1% year-over-year, from $16.46M to $43.97M.
What is the long-term trend for ImmunityBio, Inc.'s gross profit?: Over 3 years (2022 to 2025), ImmunityBio, Inc.'s gross profit has grown at a 676.9% compound annual growth rate (CAGR), from $240K to $112.54M.